2022 Revenues ($USD) : $28,541,400,000.00
2022 R&D spend : $7,190,800,000.00
2022 Number of Employees : 39,000
Fiscal Year End : 12/31/22
Leader : CEO David Ricks

Founded in 1876, Eli Lilly demonstrated strong top- and bottom-line growth in 2022, overcoming challenges such as the Alimta loss of exclusivity in the U.S. and significant foreign exchange headwinds. Entering 2023, the company announced multiple updates to its late-stage pipeline, including FDA submissions for pirtobrutinib and Alzheimer's drug candidate donanemab. The former scored an FDA approval for certain patients with relapsed or refractory mantle cell lymphoma in January 2023. Despite receiving a complete response letter for donanemab, Lilly remains optimistic about its long-term potential. Furthermore, Lilly anticipates the potential launch of two immunology assets, mirikizumab and lebrikizumab, as well as tirzepatide for obesity later in 2023. Despite setbacks, Lilly's pipeline remains robust, with the likelihood of both mirikizumab and donanemab eventually hitting the market. With a late-stage pipeline featuring nearly two dozen programs and numerous others in phase 1 or phase 2 studies, Eli Lilly's portfolio remains strong. —BB